CN To Invest $95 Million In Manitoba

Jun 18, 2021

CN Rail has announced plans to invest approximately $95 million in Manitoba in 2021 as part of CN’s $3 billion capital investment plan across its network.

In Manitoba, CN’s investment will focus on technology and infrastructure maintenance to enhance safety and the fluidity of its network.

Maintenance program highlights include:

Replacing 29 miles of rail;
Installing approximately 118,000 new railroad ties;
Rebuilding 17 road crossing surfaces; and
Maintenance work on bridges, culverts, signal systems, and other track infrastructure

In a news release, CN Rail says the proposed end-to-end merger between CN and Kansas City Southern will create a transportation network across North America, enhancing competition, spurring economic growth and delivering benefits to the local communities in which both railroads operate.

Click here to see more...

Video: New Solution Powers Efficient Pork Growth

Alltech has introduced Olerix, an innovative phytogenic blend created to promote growth and feed efficiency in pigs. Through a proprietary coating process, the bioactive blend of phytogenic compounds used in Olerix is designed to outlast the manufacturing process, ensuring consistent outcomes from feed to finish. The result is a high-impact efficiency solution that provides consistent support for gut health, feed efficiency, immune function and growth performance. Olerix is backed by validated trials conducted under modern pork production conditions.

“As the industry searches for technology to drive profitability forward in a more sustainable manner, we’re thrilled to join that effort with our Olerix technology,” said Mark Hulsebus, general manager for U.S. pork at Alltech. “Our work in this phytogenic space is yielding very encouraging results, and we’re excited to make this new opportunity available to pork producers focused on optimizing feed efficiency and growth rates.”

“Olerix represents the next generation of phytogenic technology — combining feed efficiency, livability and immune support into a practical commercial solution producers can implement today,” said Andy Rash, U.S. monogastric director at Alltech.